PMID- 27956547
OWN - NLM
STAT- MEDLINE
DCOM- 20190125
LR  - 20190125
IS  - 1468-2982 (Electronic)
IS  - 0333-1024 (Linking)
VI  - 38
IP  - 2
DP  - 2018 Feb
TI  - Antiepileptic drugs in migraine and epilepsy: Who is at increased risk of adverse 
      events?
PG  - 274-282
LID - 10.1177/0333102416683925 [doi]
AB  - Background The impact of adverse events (AEs) of antiepileptic drugs (AEDs) have 
      an impact on compliance and dropouts. We compared tolerability of AEs of AEDs 
      among patients with migraine, epilepsy, or both. Methods Overall, 335 patients 
      (epilepsy (n = 142), migraine (n = 131), and both (n = 62)), were evaluated with 
      the Liverpool Adverse Events Profile (LAEP) to assess the magnitude, profile and 
      occurrence rate of the AEs of valproate, topiramate, and lamotrigine. Results AEs 
      were significantly more common with topiramate treatment (71.0%) and among 
      migraineurs (69.5%), the latter being more prone to discontinue AEDs (46.6%). The 
      profile of AEs with topiramate and valproate differed among groups. Moreover, 
      treatment with both topiramate and valproate was associated, for all groups, with 
      a worse tolerability profile compared to lamotrigine. Conclusion Our data suggest 
      a specific drug and disease AE profile of AEDs. Specifically, migraineurs are the 
      most affected by AEs, even though they receive very low dosages of AEDs. This 
      finding might be considered a clinical implication of central sensitization 
      mechanisms. Both the profile and tolerability of AEs, highly influencing quality 
      of life, depended on the underlying conditions, and deeply impacted on treatment 
      dropout. Therefore, before starting, switching or stopping AED treatment, all 
      options need to be considered.
FAU - Romoli, Michele
AU  - Romoli M
AD  - 1 Neurology Clinic, University Hospital of Perugia, Italy.
FAU - Costa, Cinzia
AU  - Costa C
AD  - 1 Neurology Clinic, University Hospital of Perugia, Italy.
FAU - Siliquini, Sabrina
AU  - Siliquini S
AD  - 1 Neurology Clinic, University Hospital of Perugia, Italy.
FAU - Corbelli, Ilenia
AU  - Corbelli I
AD  - 1 Neurology Clinic, University Hospital of Perugia, Italy.
FAU - Eusebi, Paolo
AU  - Eusebi P
AD  - 2 Regional Health Authority of Umbria, Perugia, Italy.
FAU - Bedetti, Chiara
AU  - Bedetti C
AD  - 1 Neurology Clinic, University Hospital of Perugia, Italy.
FAU - Caproni, Stefano
AU  - Caproni S
AD  - 1 Neurology Clinic, University Hospital of Perugia, Italy.
FAU - Cupini, Letizia Maria
AU  - Cupini LM
AD  - 3 Neurology Division, Sant'Eugenio Hospital, Rome, Italy.
FAU - Calabresi, Paolo
AU  - Calabresi P
AD  - 1 Neurology Clinic, University Hospital of Perugia, Italy.
FAU - Sarchielli, Paola
AU  - Sarchielli P
AD  - 1 Neurology Clinic, University Hospital of Perugia, Italy.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20161212
PL  - England
TA  - Cephalalgia
JT  - Cephalalgia : an international journal of headache
JID - 8200710
RN  - 0 (Anticonvulsants)
RN  - 0H73WJJ391 (Topiramate)
RN  - 614OI1Z5WI (Valproic Acid)
RN  - U3H27498KS (Lamotrigine)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Anticonvulsants/*adverse effects
MH  - Child
MH  - Epilepsy/*drug therapy
MH  - Female
MH  - Humans
MH  - Lamotrigine/adverse effects
MH  - Male
MH  - Middle Aged
MH  - Migraine Disorders/*drug therapy
MH  - Topiramate/adverse effects
MH  - Valproic Acid/adverse effects
MH  - Young Adult
OTO - NOTNLM
OT  - Tolerability
OT  - adverse events
OT  - antiepileptic drugs
OT  - epilepsy
OT  - migraine
OT  - neuropharmacology
EDAT- 2016/12/14 06:00
MHDA- 2019/01/27 06:00
CRDT- 2016/12/14 06:00
PHST- 2016/12/14 06:00 [pubmed]
PHST- 2019/01/27 06:00 [medline]
PHST- 2016/12/14 06:00 [entrez]
AID - 0333102416683925 [pii]
AID - 10.1177/0333102416683925 [doi]
PST - ppublish
SO  - Cephalalgia. 2018 Feb;38(2):274-282. doi: 10.1177/0333102416683925. Epub 2016 Dec 
      12.